As a Network Lead Participating Site, the Stanford Cancer Institute (SCI) will provide overall leadership to ensure the collaboration and success of the U10 leadership team and of individual investigators who are active in enrolling patients onto cooperative group studies as participants in the NCTN. Stanford has a long history of active participation across multiple NCTN cooperative groups as evidenced by a strong publication lists and clinical trial enrollment. With this history and with the strong support from SCI leadership, a well-functioning and centralized CCTO, strong basic science and translational medicine, and increasing support for clinical research from Stanford Hospitals and Clinics, Stanford investigators are poised to continue their leadership and markedly enhance accrual to cooperative group studies in the NCTN.

Public Health Relevance

The translation of scientific ideas into therapies that bring new hope to cancer patients is a central aspect of the Stanford Cancer Institute's and mission and those of other NCI-designated cancer centers. SCI's Participation as a Lead Academic Participating Site in the NCTN will create critical synergies that will help fulfills that mission t NCTN, SCI and other cancer centers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180816-01
Application #
8605353
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-06-19
Project End
2019-02-28
Budget Start
2014-06-19
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$576,471
Indirect Cost
$217,299
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305